- Home
- Reports
- Healthcare
- Pericaditis Market
Pericaditis Market: By Type (Acute Pericarditis, Chronic Pericarditis and Recurrent Pericarditis), By Diagnosis and Treatment [Diagnosis (Electrocardiogram (ECG), Echocardiogram, Computerized Tomography (CT), and X-Ray), Treatment (Medication and Surgical Treatment)], By End User (Hospitals and Clinics, Medical Institutes, Research Organizations and Others) and By Region - Global Forecast Till 2027
ID: MRFR/HC/5746-CR | January 2019 | Region: Global | 156 pages
Market Snapshot
MRFR’s study projects a strong growth for the global pericarditis market during the forecast period (2018-2023). Growing prevalence of cardiac disorders worldwide and improving healthcare infrastructure in emerging economies creating opportunities for market players. Americas continues to be the key investment destination for drug companies, with countries such as the U.S., Canada, Mexico and Brazil occupying the leading spots. On a global level, the pericarditis market stood at a valuation of USD 1,750.38 Mn in 2017. Opportunities are likely to get better in emerging markets such as China and India in the forthcoming years. Rising healthcare spending and increased healthcare penetration is providing an impetus to the market in these countries.
Synopsis
This MRFR study presents a holistic viewpoint of the global pericarditis market. A revenue forecast for five-years (2018-2023) is also included in the study. It thoroughly discusses all the elements that may have some sort of impact on the market during the assessment period. The scope of the discussion also covers different types of pericarditis such as acute pericarditis, chronic pericarditis and recurrent pericarditis. In addition, study shed a light on diagnosis and treatment options available.
Companies Covered
Novartis International AG, Pfizer Inc., AstraZeneca Plc., PerkinElmer, Inc., Sanofi, Johnson & Johnson Services, Inc., Reckitt Benckiser Group Plc, FUJIFILM Holdings Corporation, Bayer AG, Merck & Co., Inc. and Allergan plc.
The report offers insights into the leading market players and presents an assessment of their current market position. Company information with regards to revenue, segmental share, geographical income, SWOT, growth strategies, new product launch, M&A activities, and the latest R&D initiatives is also available in the report.
Research Methodology
MRFR relies on a robust research model for conducting industry analysis. The analysis pattern may differ from sector to sector, but the fundamental structure remains unshaken. Emphasis is placed on maintaining a deep-diving research dogma. For this, interviews and meetings are conducted with opinion holders, thought leaders, and key executives. Also, data is collected from secondary research materials such as SEC filings, dossiers, paid database services, annual report published by industry leaders, etc. The gathered data undergoes a multi-level evaluation process making it error-free. In addition, both top-down and bottom-up approaches are applied to add value to research findings.
Other Description
- Market Denomination- USD Mn
- Base Year- 2017
- Forecast Period- from 2018 to 2023
For the scope of the research, MRFR’s report offers a comprehensive segmental analysis of the global market for pericarditis
By Type
- Acute Pericarditis
- Chronic Pericarditis
- Recurrent Pericarditis
By Diagnosis and Treatment
- Diagnosis
- Electrocardiogram (ECG)
- Echocardiogram
- Computerized tomography (CT)
- X-Ray
- Treatment
- Medication
- Surgical treatment
By End User
- Hospitals and Clinics
- Medical institutes
- Research organizations
- Others
By Region
- North America
- Europe
- Asia Pacific
- The Middle East & Africa (MEA)
- Latin America
Frequently Asked Questions (FAQ) :
Pericaditis market is projected to grow at a 7.96% CAGR between 2020-2027.
Pericaditis market is predicted to touch USD 2,741.39 million by 2023.
The Americas is expected to lead the pericaditis market.
Favorable reimbursement and the advent of robot-assisted cardiac surgeries are the key factors driving the pericaditis market.
Certain side effects may limit the pericaditis market.
The Global pericarditis market has a significant growth potential. As per the research findings, the market is projected to stand at over USD 2, 700 Mn by the year 2023 up from USD 1,750.38 Mn in 2017. Factors such as increasing prevalence of cardiovascular diseases and improving reimbursement policies are deeply linked with the uptick in demand for pericarditis treatment and care. There is a sharp rise in the incidence of cardiovascular diseases, a backlash of rising obesity and diabetes cases. The risk of developing a pericarditis issue is significantly high if the individual is suffering from any of the chronic ailments mentioned above. As per the American Heart Association, nearly 92.1 million Americans were diagnosed with cardiovascular diseases in 2017. It also stated that the prevalence is found to be higher in men than in women. Furthermore, in the same year, more than 92% of the patients exhibited major symptoms of heart diseases such as chest pain, heartburns, and strokes.
Improved penetration of healthcare services in third-world countries is also reflecting favorably on the market. Moreover, policy markers in developing countries are actively focusing on bolstering the healthcare domain as a part of delivering better governance. In recent years, medical reimbursement policies have continued to improve in both advance and developing countries. As per the Center for Disease Control and Prevention (CDC),65% of the people under the age of 65 had private insurance while 26.35% of people had public insurance in the US in 2017. Despite the increased market opportunity, players are likely face challenges in front such as drug safety and product approvals.
Segmental Analysis
Segmental analysis of the market is conducted on the basis of type, diagnosis & treatment, end-user and region. Based on type, the pericarditis market is segmented into acute pericarditis, chronic pericarditis, and recurrent pericarditis. The acute pericarditis segment is projected to reach a market valuation of USD 1,365.94 Mn by 2023-end. Acute pericarditis refers to the inflammation of the pericardial sac and is a common pericardium disorder. The recurrent pericarditis segment is expected to exhibit the highest CAGR during the assessment period.
Based on diagnosis and treatment, the pericarditis market is segmented into diagnosis and treatment. The diagnosis segment is further sub-segment into electrocardiogram (ECG), echocardiogram, computerized tomography (CT) and X-Ray. The treatment segment is further sub-segmented into medication and surgical treatment. The treatment is likely to retain its dominant position throughout the forecast period as well as reflect a strong growth rate.
Based on end user, the global pericarditis market is segmented into hospitals and clinics, medical institutes & research organizations, and others. The hospitals and clinics segment is projected to reach USD 1,323.16 million by the end of 2023, increasing at a CAGR of 8.05%from 2018 to 2023. In 2017, the hospital segment accounted 48.01% market share in terms of value. The medical institutes & research organization segment currently holds the second spot and is projected to witness a relatively higher CAGR.
Regional Analysis
On the basis of region, the global pericarditis market has been segmented into four key regions, which include Americas, Europe, Asia-Pacific (APAC), and the Middle East and Africa (MEA). The Americas currently account for the largest share of the global pericarditis market. On the back of rising healthcare spending and growing insurance coverage, demand for pericarditis treatment has continued to grow. Moreover, presence of robust healthcare system and a massive patient pool is creating opportunities for market players. North America is followed by Europe - the second largest market for pericarditis. Fueled buy the increased prevalence of pericarditis in both West and East European countries, the region’s market reached a valuation of USD 540.97 Mn in 2017. Meanwhile, the market in APAC is expected to post the highest CAGR during the assessment period. Rising level of awareness coupled with improving healthcare services has opened new avenues for market players operating in the region.
Competition Tracking
Some of the key companies operating in the global pericarditis market include Pfizer Inc., Reckitt Benckiser Group Plc, Novartis International AG, Allergan plc., AstraZeneca Plc., Bayer AG, PerkinElmer, Inc., FUJIFILM Holdings Corporation, Merck & Co., Inc., Sanofi, and Johnson & Johnson Services, Inc.
1 Report Prologue
2 Market Introduction
2.1 Scope of the Study 17
2.2 List of Assumptions 17
2.3 Market Structure 18
3 Research Methodology
3.1 Research Process 20
3.2 Primary Research 21
3.3 Secondary Research 22
3.4 Market Size Estimation 23
3.5 Forecast Model 23
4 Market Dynamics
4.1 Introduction 25
4.2 Drivers 25
4.2.1 Increasing prevalence of cardiovascular diseases such as heart attack & hypertension 25
4.2.2 Favorable reimbursement policies 26
4.2.3 Increasing preference for minimally invasive procedures 26
4.3 Restraints 26
4.3.1 Side-effects of anti-inflammatory drugs 26
4.3.2 Risk of bacterial infections 27
4.4 Opportunity 27
4.4.1 Robot-assisted surgery will be a technological milestone 27
4.5 Challenges 27
4.5.1 Expiration of blockbuster drugs 27
4.6 Macroeconomic indicators 28
4.7 Technological Trends & Assessments 28
5 Market Factor Analysis
5.1 Porter’s Five Forces Analysis 30
5.1.1 Bargaining Power of Suppliers 30
5.1.2 Bargaining Power of Buyers 31
5.1.3 Threat of New Entrants 31
5.1.4 Threat of Substitutes 31
5.1.5 Intensity of Rivalry 31
5.2 Supply Chain Analysis 32
5.2.1 R&D 32
5.2.2 Manufacturing 32
5.2.3 Distribution 32
5.2.4 Marketing & Sales 32
5.2.5 Post-Sales Monitoring 33
5.3 Investment Feasibility Analysis 33
6 Pericarditis Market, by Type
6.1 Introduction 35
6.2 Acute pericarditis 36
6.3 Recurrent pericarditis 37
6.4 Chronic pericarditis 38
7 Pericarditis Market, by Diagnosis & Treatment
7.1 Introduction 40
7.2 Diagnosis 41
7.2.1 Electrocardiogram (ECG) 42
7.2.2 Echocardiogram 43
7.2.3 Computerized tomography (CT) 43
7.2.4 X-Ray 44
7.3 Treatment 45
7.3.1 Medication 46
7.3.1.1 Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) 47
7.3.1.2 Colchicine 47
7.3.2 Surgical treatment 48
8 Pericarditis Market, by End User
8.1 Introduction 50
8.2 Hospitals & Clinics 51
8.3 Medical Institutes & Research laboratories 52
9 Global Pericarditis Market, By Region
9.1 Introduction 54
9.2 Americas 56
Pericarditis Market, by Type
Pericarditis Market, by Diagnosis & Treatment
Pericarditis Market, by End User
9.2.1 North America 60
Pericarditis Market, by Type
Pericarditis Market, by Diagnosis & Treatment
Pericarditis Market, by End User
9.2.1.1 US 63
Pericarditis Market, by Type
Pericarditis Market, by Diagnosis & Treatment
Pericarditis Market, by End User
9.2.1.2 Canada 66
Pericarditis Market, by Type
Pericarditis Market, by Diagnosis & Treatment
Pericarditis Market, by End User
9.2.2 South America 68
Pericarditis Market, by Type
Pericarditis Market, by Diagnosis & Treatment
Pericarditis Market, by End User
9.3 Europe 72
Pericarditis Market, by Type
Pericarditis Market, by Diagnosis & Treatment
Pericarditis Market, by End User
9.3.1 Western Europe 75
Pericarditis Market, by Type
Pericarditis Market, by Diagnosis & Treatment
Pericarditis Market, by End User
9.3.1.1 Germany 79
Pericarditis Market, by Type
Pericarditis Market, by Diagnosis & Treatment
Pericarditis Market, by End User
9.3.1.2 France 81
Pericarditis Market, by Type
Pericarditis Market, by Diagnosis & Treatment
Pericarditis Market, by End User
9.3.1.3 UK 84
Pericarditis Market, by Type
Pericarditis Market, by Diagnosis & Treatment
Pericarditis Market, by End User
9.3.1.4 Italy 86
Pericarditis Market, by Type
Pericarditis Market, by Diagnosis & Treatment
Pericarditis Market, by End User
9.3.1.5 Spain 89
Pericarditis Market, by Type
Pericarditis Market, by Diagnosis & Treatment
Pericarditis Market, by End User
9.3.1.6 Rest of Western Europe 91
Pericarditis Market, by Type
Pericarditis Market, by Diagnosis & Treatment
Pericarditis Market, by End User
9.3.2 Eastern Europe 94
Pericarditis Market, by Type
Pericarditis Market, by Diagnosis & Treatment
Pericarditis Market, by End User
9.4 Asia-Pacific 97
Pericarditis Market, by Type
Pericarditis Market, by Diagnosis & Treatment
Pericarditis Market, by End User
9.4.1 Japan 100
Pericarditis Market, by Type
Pericarditis Market, by Diagnosis & Treatment
Pericarditis Market, by End User
9.4.2 China 102
Pericarditis Market, by Type
Pericarditis Market, by Diagnosis & Treatment
Pericarditis Market, by End User
9.4.3 India 105
Pericarditis Market, by Type
Pericarditis Market, by Diagnosis & Treatment
Pericarditis Market, by End User
9.4.4 Australia 108
Pericarditis Market, by Type
Pericarditis Market, by Diagnosis & Treatment
Pericarditis Market, by End User
9.4.5 South Korea 111
Pericarditis Market, by Type
Pericarditis Market, by Diagnosis & Treatment
Pericarditis Market, by End User
9.4.6 Rest of Asia Pacific 114
Pericarditis Market, by Type
Pericarditis Market, by Diagnosis & Treatment
Pericarditis Market, by End User
9.5 Middle East & Africa 117
Pericarditis Market, by Type
Pericarditis Market, by Diagnosis & Treatment
Pericarditis Market, by End User
9.5.1 Middle East 121
Pericarditis Market, by Type
Pericarditis Market, by Diagnosis & Treatment
Pericarditis Market, by End User
9.5.2 Africa 124
Pericarditis Market, by Type
Pericarditis Market, by Diagnosis & Treatment
Pericarditis Market, by End User
10 Competitive Landscape
10.1 Introduction 128
10.2 Company Ranking 128
11 Company Profile
11.1 Pfizer Inc. 130
11.1.1 Company Overview 130
11.1.2 Financial Overview 130
11.1.3 Products/Services Offered 131
11.1.4 Key Developments 131
11.1.5 SWOT Analysis 131
11.1.6 Key Strategies 132
11.2 AstraZeneca Plc 133
11.2.1 Company Overview 133
11.2.2 Financial Overview 133
11.2.3 Products/Services Offered 134
11.2.4 Key Developments 134
11.2.5 SWOT Analysis 134
11.2.6 Key Strategies 134
11.3 Bayer AG 135
11.3.1 Company Overview 135
11.3.2 Financial Overview 135
11.3.3 Products/Services Offered 136
11.3.4 Key Developments 136
11.3.5 SWOT Analysis 136
11.3.6 Key Strategies 136
11.4 Reckitt Benckiser Group Plc. 137
11.4.1 Company Overview 137
11.4.2 Financial Overview 137
11.4.3 Products/Services Offered 138
11.4.4 Key Developments 138
11.4.5 SWOT Analysis 138
11.4.6 Key Strategies 138
11.5 PerkinElmer, Inc. 139
11.5.1 Company Overview 139
11.5.2 Financial Overview 139
11.5.3 Products/Services Offered 140
11.5.4 Key Developments 140
11.5.5 SWOT Analysis 140
11.5.6 Key Strategies 140
11.6 Novartis International AG 141
11.6.1 Financial Overview 141
11.6.2 Products/Services Offered 142
11.6.3 Key Developments 142
11.6.4 SWOT Analysis 142
11.6.5 Key Strategies 142
11.7 FUJIFILM Holdings Corporation 143
11.7.1 Company Overview 143
11.7.2 Financial Overview 143
11.7.3 Products/Services Offered 144
11.7.4 Key Developments 144
11.7.5 SWOT Analysis 144
11.7.6 Key Strategies 144
11.8 Allergan plc. 145
11.8.1 Company Overview 145
11.8.2 Financial Overview 145
11.8.3 Products/Services Offered 146
11.8.4 SWOT Analysis 146
11.8.5 Key Developments 146
11.8.6 Key Strategies 146
11.9 Merck & Co., Inc. 147
11.9.1 Company Overview 147
11.9.2 Financial Overview 147
11.9.3 Products/Services Offered 148
11.9.4 Key Developments 148
11.9.5 SWOT Analysis 148
11.9.6 Key Strategies 148
11.10 Sanofi 149
11.10.1 Company Overview 149
11.10.2 Financial Overview 149
11.10.3 Products/Services Offered 150
11.10.4 Key Developments 150
11.10.5 SWOT Analysis 150
11.10.6 Key Strategies 150
11.11 Johnson & Johnson Services, Inc. 151
11.11.1 Company Overview 151
11.11.2 Financial Overview 151
11.11.3 Products/Services Offered 152
11.11.4 Key Developments 152
11.11.5 SWOT Analysis 152
11.11.6 Key Strategies 152
12 Appendix
12.1 Discussion Blue Print 154
13 List of Tables
TABLE 1 MARKET SYNOPSIS 15
TABLE 2 LIST OF ASSUMPTIONS 17
TABLE 3 GLOBAL PERICARDITIS MARKET, BY TYPE 2020-2027 (USD MILLION) 35
TABLE 4 GLOBAL PERICARDITIS MARKET FOR ACUTE PERICARDITIS, BY REGION 2020-2027 (USD MILLION) 36
TABLE 5 GLOBAL PERICARDITIS MARKET FOR ACUTE PERICARDITIS, BY REGION 2020-2027 (USD MILLION) 37
TABLE 6 GLOBAL PERICARDITIS MARKET FOR ACUTE PERICARDITIS, BY REGION 2020-2027 (USD MILLION) 38
TABLE 7 GLOBAL PERICARDITIS MARKET, BY DIAGNOSIS & TREATMENT 2020-2027 (USD MILLION) 40
TABLE 8 GLOBAL PERICARDITIS MARKET FOR DIAGNOSIS, BY TYPE 2020-2027 (USD MILLION) 41
TABLE 9 GLOBAL PERICARDITIS MARKET FOR DIAGNOSIS, BY REGION 2020-2027 (USD MILLION) 41
TABLE 10 GLOBAL PERICARDITIS MARKET FOR ELECTROCARDIOGRAM (ECG), BY REGION 2020-2027 (USD MILLION) 42
TABLE 11 GLOBAL PERICARDITIS MARKET FOR ECHOCARDIOGRAM, BY REGION 2020-2027 (USD MILLION) 43
TABLE 12 GLOBAL PERICARDITIS MARKET FOR CT, BY REGION 2020-2027 (USD MILLION) 43
TABLE 13 GLOBAL PERICARDITIS MARKET FOR X-RAY, BY REGION 2020-2027 (USD MILLION) 44
TABLE 14 GLOBAL PERICARDITIS MARKET FOR TREATMENT, BY TYPE 2020-2027 (USD MILLION) 45
TABLE 15 GLOBAL PERICARDITIS MARKET FOR TREATMENT, BY REGION 2020-2027 (USD MILLION) 45
TABLE 16 GLOBAL PERICARDITIS MARKET FOR MEDICATION, BY TYPE 2020-2027 (USD MILLION) 46
TABLE 17 GLOBAL PERICARDITIS MARKET FOR MEDICATION, BY REGION 2020-2027 (USD MILLION) 46
TABLE 18 GLOBAL PERICARDITIS MARKET FOR NON-STEROIDAL ANTI-INFLAMMATORY DRUGS (NSAIDS), BY REGION 2020-2027 (USD MILLION) 47
TABLE 19 GLOBAL PERICARDITIS MARKET FOR COLCHICINE, BY REGION 2020-2027 (USD MILLION) 47
TABLE 20 GLOBAL PERICARDITIS MARKET FOR SURGICAL TREATMENT, BY REGION 2020-2027 (USD MILLION) 48
TABLE 21 GLOBAL PERICARDITIS MARKET, BY END-USER 2020-2027 (USD MILLION) 50
TABLE 22 GLOBAL PERICARDITIS MARKET FOR HOSPITALS & CLINICS, BY REGION 2020-2027 (USD MILLION) 51
TABLE 23 GLOBAL PERICARDITIS MARKET FOR MEDICAL INSTITUTES & RESEARCH LABORATORIES, BY REGION 2020-2027 (USD MILLION) 52
TABLE 24 GLOBAL PERICARDITIS MARKET, BY REGION 2020-2027 (USD MILLION) 55
TABLE 25 AMERICAS PERICARDITIS MARKET BY REGION, 2020 TO 2027 (USD MILLION) 56
TABLE 26 AMERICAS PERICARDITIS MARKET BY TYPE, 2020 TO 2027 (USD MILLION) 57
TABLE 27 AMERICAS PERICARDITIS MARKET BY DIAGNOSIS & TREATMENT, 2020 TO 2027 (USD MILLION) 57
TABLE 28 AMERICAS PERICARDITIS MARKET BY DIAGNOSIS TYPE, 2020 TO 2027 (USD MILLION) 58
TABLE 29 AMERICAS PERICARDITIS MARKET BY TREATMENT TYPE, 2020 TO 2027 (USD MILLION) 58
TABLE 30 AMERICAS PERICARDITIS MARKET BY MEDICATION TYPE, 2020 TO 2027 (USD MILLION) 59
TABLE 31 AMERICAS PERICARDITIS MARKET BY END-USER, 2020 TO 2027 (USD MILLION) 59
TABLE 32 NORTH AMERICA PERICARDITIS MARKET BY COUNTRY, 2020 TO 2027 (USD MILLION) 60
TABLE 33 NORTH AMERICA PERICARDITIS MARKET BY TYPE, 2020 TO 2027 (USD MILLION) 60
TABLE 34 NORTH AMERICA PERICARDITIS MARKET BY DIAGNOSIS & TREATMENT, 2020 TO 2027 (USD MILLION) 61
TABLE 35 NORTH AMERICA PERICARDITIS MARKET BY DIAGNOSIS TYPE, 2020 TO 2027 (USD MILLION) 61
TABLE 36 NORTH AMERICA PERICARDITIS MARKET BY TREATMENT TYPE, 2020 TO 2027 (USD MILLION) 61
TABLE 37 NORTH AMERICA PERICARDITIS MARKET BY MEDICATION TYPE, 2020 TO 2027 (USD MILLION) 62
TABLE 38 NORTH AMERICA PERICARDITIS MARKET BY END-USER, 2020 TO 2027 (USD MILLION) 62
TABLE 39 US PERICARDITIS MARKET BY TYPE, 2020 TO 2027 (USD MILLION) 63
TABLE 40 US PERICARDITIS MARKET BY DIAGNOSIS & TREATMENT, 2020 TO 2027 (USD MILLION) 63
TABLE 41 US PERICARDITIS MARKET BY DIAGNOSIS TYPE, 2020 TO 2027 (USD MILLION) 63
TABLE 42 US PERICARDITIS MARKET BY TREATMENT TYPE, 2020 TO 2027 (USD MILLION) 64
TABLE 43 US PERICARDITIS MARKET BY MEDICATION TYPE, 2020 TO 2027 (USD MILLION) 64
TABLE 44 US PERICARDITIS MARKET BY END-USER, 2020 TO 2027 (USD MILLION) 65
TABLE 45 CANADA PERICARDITIS MARKET BY TYPE, 2020 TO 2027 (USD MILLION) 66
TABLE 46 CANADA PERICARDITIS MARKET BY DIAGNOSIS & TREATMENT, 2020 TO 2027 (USD MILLION) 66
TABLE 47 CANADA PERICARDITIS MARKET BY DIAGNOSIS TYPE, 2020 TO 2027 (USD MILLION) 66
TABLE 48 CANADA PERICARDITIS MARKET BY TREATMENT TYPE, 2020 TO 2027 (USD MILLION) 67
TABLE 49 CANADA PERICARDITIS MARKET BY MEDICATION TYPE, 2020 TO 2027 (USD MILLION) 67
TABLE 50 CANADA PERICARDITIS MARKET BY END-USER, 2020 TO 2027 (USD MILLION) 68
TABLE 51 SOUTH AMERICA PERICARDITIS MARKET BY TYPE, 2020 TO 2027 (USD MILLION) 68
TABLE 52 SOUTH AMERICA PERICARDITIS MARKET BY DIAGNOSIS & TREATMENT, 2020 TO 2027 (USD MILLION) 69
TABLE 53 SOUTH AMERICA PERICARDITIS MARKET BY DIAGNOSIS TYPE, 2020 TO 2027 (USD MILLION) 69
TABLE 54 SOUTH AMERICA PERICARDITIS MARKET BY TREATMENT TYPE, 2020 TO 2027 (USD MILLION) 70
TABLE 55 SOUTH AMERICA PERICARDITIS MARKET BY MEDICATION TYPE, 2020 TO 2027 (USD MILLION) 70
TABLE 56 SOUTH AMERICA PERICARDITIS MARKET BY END-USER, 2020 TO 2027 (USD MILLION) 71
TABLE 57 EUROPE PERICARDITIS MARKET BY REGION, 2020 TO 2027 (USD MILLION) 72
TABLE 58 EUROPE PERICARDITIS MARKET BY TYPE, 2020 TO 2027 (USD MILLION) 73
TABLE 59 EUROPE PERICARDITIS MARKET BY DIAGNOSIS & TREATMENT, 2020 TO 2027 (USD MILLION) 73
TABLE 60 EUROPE PERICARDITIS MARKET BY DIAGNOSIS TYPE, 2020 TO 2027 (USD MILLION) 73
TABLE 61 EUROPE PERICARDITIS MARKET BY TREATMENT TYPE, 2020 TO 2027 (USD MILLION) 74
TABLE 62 EUROPE PERICARDITIS MARKET BY MEDICATION TYPE, 2020 TO 2027 (USD MILLION) 74
TABLE 63 EUROPE PERICARDITIS MARKET BY END-USER, 2020 TO 2027 (USD MILLION) 75
TABLE 64 WESTERN EUROPE PERICARDITIS MARKET BY COUNTRY, 2020 TO 2027 (USD MILLION) 76
TABLE 65 WESTERN EUROPE PERICARDITIS MARKET BY TYPE, 2020 TO 2027 (USD MILLION) 76
TABLE 66 WESTERN EUROPE PERICARDITIS MARKET BY DIAGNOSIS & TREATMENT, 2020 TO 2027 (USD MILLION) 77
TABLE 67 WESTERN EUROPE PERICARDITIS MARKET BY DIAGNOSIS TYPE, 2020 TO 2027 (USD MILLION) 77
TABLE 68 WESTERN EUROPE PERICARDITIS MARKET BY TREATMENT TYPE, 2020 TO 2027 (USD MILLION) 77
TABLE 69 WESTERN EUROPE PERICARDITIS MARKET BY MEDICATION TYPE, 2020 TO 2027 (USD MILLION) 78
TABLE 70 WESTERN EUROPE PERICARDITIS MARKET BY END-USER, 2020 TO 2027 (USD MILLION) 78
TABLE 71 GERMANY PERICARDITIS MARKET BY TYPE, 2020 TO 2027 (USD MILLION) 79
TABLE 72 GERMANY PERICARDITIS MARKET BY DIAGNOSIS & TREATMENT, 2020 TO 2027 (USD MILLION) 79
TABLE 73 GERMANY PERICARDITIS MARKET BY DIAGNOSIS TYPE, 2020 TO 2027 (USD MILLION) 79
TABLE 74 GERMANY PERICARDITIS MARKET BY TREATMENT TYPE, 2020 TO 2027 (USD MILLION) 80
TABLE 75 GERMANY PERICARDITIS MARKET BY MEDICATION TYPE, 2020 TO 2027 (USD MILLION) 80
TABLE 76 GERMANY PERICARDITIS MARKET BY END-USER, 2020 TO 2027 (USD MILLION) 81
TABLE 77 FRANCE PERICARDITIS MARKET BY TYPE, 2020 TO 2027 (USD MILLION) 81
TABLE 78 FRANCE PERICARDITIS MARKET BY DIAGNOSIS & TREATMENT, 2020 TO 2027 (USD MILLION) 81
TABLE 79 FRANCE PERICARDITIS MARKET BY DIAGNOSIS TYPE, 2020 TO 2027 (USD MILLION) 82
TABLE 80 FRANCE PERICARDITIS MARKET BY TREATMENT TYPE, 2020 TO 2027 (USD MILLION) 82
TABLE 81 FRANCE PERICARDITIS MARKET BY MEDICATION TYPE, 2020 TO 2027 (USD MILLION) 83
TABLE 82 FRANCE PERICARDITIS MARKET BY END-USER, 2020 TO 2027 (USD MILLION) 83
TABLE 83 UK PERICARDITIS MARKET BY TYPE, 2020 TO 2027 (USD MILLION) 84
TABLE 84 UK PERICARDITIS MARKET BY DIAGNOSIS & TREATMENT, 2020 TO 2027 (USD MILLION) 84
TABLE 85 UK PERICARDITIS MARKET BY DIAGNOSIS TYPE, 2020 TO 2027 (USD MILLION) 84
TABLE 86 UK PERICARDITIS MARKET BY TREATMENT TYPE, 2020 TO 2027 (USD MILLION) 85
TABLE 87 UK PERICARDITIS MARKET BY MEDICATION TYPE, 2020 TO 2027 (USD MILLION) 85
TABLE 88 UK PERICARDITIS MARKET BY END-USER, 2020 TO 2027 (USD MILLION) 86
TABLE 89 ITALY PERICARDITIS MARKET BY TYPE, 2020 TO 2027 (USD MILLION) 86
TABLE 90 ITALY PERICARDITIS MARKET BY DIAGNOSIS & TREATMENT, 2020 TO 2027 (USD MILLION) 86
TABLE 91 ITALY PERICARDITIS MARKET BY DIAGNOSIS TYPE, 2020 TO 2027 (USD MILLION) 87
TABLE 92 ITALY PERICARDITIS MARKET BY TREATMENT TYPE, 2020 TO 2027 (USD MILLION) 87
TABLE 93 ITALY PERICARDITIS MARKET BY MEDICATION TYPE, 2020 TO 2027 (USD MILLION) 88
TABLE 94 ITALY PERICARDITIS MARKET BY END-USER, 2020 TO 2027 (USD MILLION) 88
TABLE 95 SPAIN PERICARDITIS MARKET BY TYPE, 2020 TO 2027 (USD MILLION) 89
TABLE 96 SPAIN PERICARDITIS MARKET BY DIAGNOSIS & TREATMENT, 2020 TO 2027 (USD MILLION) 89
TABLE 97 SPAIN PERICARDITIS MARKET BY DIAGNOSIS TYPE, 2020 TO 2027 (USD MILLION) 89
TABLE 98 SPAIN PERICARDITIS MARKET BY TREATMENT TYPE, 2020 TO 2027 (USD MILLION) 90
TABLE 99 SPAIN PERICARDITIS MARKET BY MEDICATION TYPE, 2020 TO 2027 (USD MILLION) 90
TABLE 100 SPAIN PERICARDITIS MARKET BY END-USER, 2020 TO 2027 (USD MILLION) 91
TABLE 101 REST OF WESTERN EUROPE PERICARDITIS MARKET BY TYPE, 2020 TO 2027 (USD MILLION) 91
TABLE 102 REST OF WESTERN EUROPE PERICARDITIS MARKET BY DIAGNOSIS & TREATMENT, 2020 TO 2027 (USD MILLION) 91
TABLE 103 REST OF WESTERN EUROPE PERICARDITIS MARKET BY DIAGNOSIS TYPE, 2020 TO 2027 (USD MILLION) 92
TABLE 104 REST OF WESTERN EUROPE PERICARDITIS MARKET BY TREATMENT TYPE, 2020 TO 2027 (USD MILLION) 92
TABLE 105 REST OF WESTERN EUROPE PERICARDITIS MARKET BY MEDICATION TYPE, 2020 TO 2027 (USD MILLION) 93
TABLE 106 REST OF WESTERN EUROPE PERICARDITIS MARKET BY END-USER, 2020 TO 2027 (USD MILLION) 93
TABLE 107 EASTERN EUROPE PERICARDITIS MARKET BY TYPE, 2020 TO 2027 (USD MILLION) 94
TABLE 108 EASTERN EUROPE PERICARDITIS MARKET BY DIAGNOSIS & TREATMENT, 2020 TO 2027 (USD MILLION) 94
TABLE 109 EASTERN EUROPE PERICARDITIS MARKET BY DIAGNOSIS TYPE, 2020 TO 2027 (USD MILLION) 95
TABLE 110 EASTERN EUROPE PERICARDITIS MARKET BY TREATMENT TYPE, 2020 TO 2027 (USD MILLION) 95
TABLE 111 EASTERN EUROPE PERICARDITIS MARKET BY MEDICATION TYPE, 2020 TO 2027 (USD MILLION) 96
TABLE 112 EASTERN EUROPE PERICARDITIS MARKET BY END-USER, 2020 TO 2027 (USD MILLION) 96
TABLE 113 ASIA-PACIFIC PERICARDITIS MARKET BY COUNTRY, 2020 TO 2027 (USD MILLION) 97
TABLE 114 ASIA-PACIFIC PERICARDITIS MARKET BY TYPE, 2020 TO 2027 (USD MILLION) 98
TABLE 115 ASIA-PACIFIC PERICARDITIS MARKET BY DIAGNOSIS & TREATMENT, 2020 TO 2027 (USD MILLION) 98
TABLE 116 ASIA-PACIFIC PERICARDITIS MARKET BY DIAGNOSIS TYPE, 2020 TO 2027 (USD MILLION) 98
TABLE 117 ASIA-PACIFIC PERICARDITIS MARKET BY TREATMENT TYPE, 2020 TO 2027 (USD MILLION) 99
TABLE 118 ASIA-PACIFIC PERICARDITIS MARKET BY MEDICATION TYPE, 2020 TO 2027 (USD MILLION) 99
TABLE 119 ASIA-PACIFIC PERICARDITIS MARKET BY END-USER, 2020 TO 2027 (USD MILLION) 100
TABLE 120 JAPAN PERICARDITIS MARKET BY TYPE, 2020 TO 2027 (USD MILLION) 100
TABLE 121 JAPAN PERICARDITIS MARKET BY DIAGNOSIS & TREATMENT, 2020 TO 2027 (USD MILLION) 100
TABLE 122 JAPAN PERICARDITIS MARKET BY DIAGNOSIS TYPE, 2020 TO 2027 (USD MILLION) 101
TABLE 123 JAPAN PERICARDITIS MARKET BY TREATMENT TYPE, 2020 TO 2027 (USD MILLION) 101
TABLE 124 JAPAN PERICARDITIS MARKET BY MEDICATION TYPE, 2020 TO 2027 (USD MILLION) 101
TABLE 125 JAPAN PERICARDITIS MARKET BY END-USER, 2020 TO 2027 (USD MILLION) 102
TABLE 126 CHINA PERICARDITIS MARKET BY TYPE, 2020 TO 2027 (USD MILLION) 102
TABLE 127 CHINA PERICARDITIS MARKET BY DIAGNOSIS & TREATMENT, 2020 TO 2027 (USD MILLION) 103
TABLE 128 CHINA PERICARDITIS MARKET BY DIAGNOSIS TYPE, 2020 TO 2027 (USD MILLION) 103
TABLE 129 CHINA PERICARDITIS MARKET BY TREATMENT TYPE, 2020 TO 2027 (USD MILLION) 103
TABLE 130 CHINA PERICARDITIS MARKET BY MEDICATION TYPE, 2020 TO 2027 (USD MILLION) 104
TABLE 131 CHINA PERICARDITIS MARKET BY END-USER, 2020 TO 2027 (USD MILLION) 104
TABLE 132 INDIA PERICARDITIS MARKET BY TYPE, 2020 TO 2027 (USD MILLION) 105
TABLE 133 INDIA PERICARDITIS MARKET BY DIAGNOSIS & TREATMENT, 2020 TO 2027 (USD MILLION) 105
TABLE 134 INDIA PERICARDITIS MARKET BY DIAGNOSIS TYPE, 2020 TO 2027 (USD MILLION) 106
TABLE 135 INDIA PERICARDITIS MARKET BY TREATMENT TYPE, 2020 TO 2027 (USD MILLION) 106
TABLE 136 INDIA PERICARDITIS MARKET BY MEDICATION TYPE, 2020 TO 2027 (USD MILLION) 106
TABLE 137 INDIA PERICARDITIS MARKET BY END-USER, 2020 TO 2027 (USD MILLION) 107
TABLE 138 AUSTRALIA PERICARDITIS MARKET BY TYPE, 2020 TO 2027 (USD MILLION) 108
TABLE 139 AUSTRALIA PERICARDITIS MARKET BY DIAGNOSIS & TREATMENT, 2020 TO 2027 (USD MILLION) 108
TABLE 140 AUSTRALIA PERICARDITIS MARKET BY DIAGNOSIS TYPE, 2020 TO 2027 (USD MILLION) 109
TABLE 141 AUSTRALIA PERICARDITIS MARKET BY TREATMENT TYPE, 2020 TO 2027 (USD MILLION) 109
TABLE 142 AUSTRALIA PERICARDITIS MARKET BY MEDICATION TYPE, 2020 TO 2027 (USD MILLION) 109
TABLE 143 AUSTRALIA PERICARDITIS MARKET BY END-USER, 2020 TO 2027 (USD MILLION) 110
TABLE 144 SOUTH KOREA PERICARDITIS MARKET BY TYPE, 2020 TO 2027 (USD MILLION) 111
TABLE 145 SOUTH KOREA PERICARDITIS MARKET BY DIAGNOSIS & TREATMENT, 2020 TO 2027 (USD MILLION) 111
TABLE 146 SOUTH KOREA PERICARDITIS MARKET BY DIAGNOSIS TYPE, 2020 TO 2027 (USD MILLION) 112
TABLE 147 SOUTH KOREA PERICARDITIS MARKET BY TREATMENT TYPE, 2020 TO 2027 (USD MILLION) 112
TABLE 148 SOUTH KOREA PERICARDITIS MARKET BY MEDICATION TYPE, 2020 TO 2027 (USD MILLION) 112
TABLE 149 SOUTH KOREA PERICARDITIS MARKET BY END-USER, 2020 TO 2027 (USD MILLION) 113
TABLE 150 REST OF ASIA PACIFIC PERICARDITIS MARKET BY TYPE, 2020 TO 2027 (USD MILLION) 114
TABLE 151 REST OF ASIA PACIFIC PERICARDITIS MARKET BY DIAGNOSIS & TREATMENT, 2020 TO 2027 (USD MILLION) 114
TABLE 152 REST OF ASIA PACIFIC PERICARDITIS MARKET BY DIAGNOSIS TYPE, 2020 TO 2027 (USD MILLION) 115
TABLE 153 REST OF ASIA PACIFIC PERICARDITIS MARKET BY TREATMENT TYPE, 2020 TO 2027 (USD MILLION) 115
TABLE 154 REST OF ASIA PACIFIC PERICARDITIS MARKET BY MEDICATION TYPE, 2020 TO 2027 (USD MILLION) 115
TABLE 155 REST OF ASIA PACIFIC PERICARDITIS MARKET BY END-USER, 2020 TO 2027 (USD MILLION) 116
TABLE 156 MIDDLE EAST & AFRICA PERICARDITIS MARKET BY REGION, 2020 TO 2027 (USD MILLION) 117
TABLE 157 MIDDLE EAST & AFRICA PERICARDITIS MARKET BY TYPE, 2020 TO 2027 (USD MILLION) 118
TABLE 158 MIDDLE EAST & AFRICA PERICARDITIS MARKET BY DIAGNOSIS & TREATMENT, 2020 TO 2027 (USD MILLION) 118
TABLE 159 MIDDLE EAST & AFRICA PERICARDITIS MARKET BY DIAGNOSIS TYPE, 2020 TO 2027 (USD MILLION) 118
TABLE 160 MIDDLE EAST & AFRICA PERICARDITIS MARKET BY TREATMENT TYPE, 2020 TO 2027 (USD MILLION) 119
TABLE 161 MIDDLE EAST & AFRICA PERICARDITIS MARKET BY MEDICATION TYPE, 2020 TO 2027 (USD MILLION) 119
TABLE 162 MIDDLE EAST & AFRICA PERICARDITIS MARKET BY END-USER, 2020 TO 2027 (USD MILLION) 120
TABLE 163 MIDDLE EAST PERICARDITIS MARKET BY TYPE, 2020 TO 2027 (USD MILLION) 121
TABLE 164 MIDDLE EAST PERICARDITIS MARKET BY DIAGNOSIS & TREATMENT, 2020 TO 2027 (USD MILLION) 121
TABLE 165 MIDDLE EAST PERICARDITIS MARKET BY DIAGNOSIS TYPE, 2020 TO 2027 (USD MILLION) 122
TABLE 166 MIDDLE EAST PERICARDITIS MARKET BY TREATMENT TYPE, 2020 TO 2027 (USD MILLION) 122
TABLE 167 MIDDLE EAST PERICARDITIS MARKET BY MEDICATION TYPE, 2020 TO 2027 (USD MILLION) 122
TABLE 168 MIDDLE EAST PERICARDITIS MARKET BY END-USER, 2020 TO 2027 (USD MILLION) 123
TABLE 169 AFRICA PERICARDITIS MARKET BY DIAGNOSIS & TREATMENT, 2020 TO 2027 (USD MILLION) 124
TABLE 170 AFRICA PERICARDITIS MARKET BY DIAGNOSIS TYPE, 2020 TO 2027 (USD MILLION) 125
TABLE 171 AFRICA PERICARDITIS MARKET BY TREATMENT TYPE, 2020 TO 2027 (USD MILLION) 125
TABLE 172 AFRICA PERICARDITIS MARKET BY MEDICATION TYPE, 2020 TO 2027 (USD MILLION) 125
TABLE 173 AFRICA PERICARDITIS MARKET BY END-USER, 2020 TO 2027 (USD MILLION) 126
TABLE 174 TOP MANUFACTURERS IN THE GLOBAL PERICARDITIS MARKET 128
14 List of Figures
FIGURE 1 GLOBAL PERICARDITIS MARKET: MARKET STRUCTURE 18
FIGURE 2 RESEARCH PROCESS OF MRFR 20
FIGURE 3 TOP-DOWN & BOTTOM-UP APPROACHES 23
FIGURE 4 PORTER’S FIVE FORCES ANALYSIS OF THE GLOBAL PERICARDITIS MARKET 30
FIGURE 5 SUPPLY CHAIN: PERICARDITIS MARKET 32
FIGURE 6 GLOBAL PERICARDITIS MARKET, BY TYPE 2020 & 2027 35
FIGURE 7 GLOBAL PERICARDITIS MARKET, BY DIAGNOSIS & TREATMENT 2020 & 2027 40
FIGURE 8 GLOBAL PERICARDITIS MARKET, BY END-USER 2020 & 2027 50
FIGURE 9 GLOBAL PERICARDITIS MARKET BY REGION, 2020 & 2027 (USD MILLION) 54
FIGURE 10 AMERICAS PERICARDITIS MARKET SHARE, BY REGION, 2020 (%) 56
FIGURE 11 NORTH AMERICA PERICARDITIS MARKET SHARE BY REGION, 2020 (%) 60
FIGURE 12 EUROPE PERICARDITIS MARKET SHARE BY REGION, 2020 (%) 72
FIGURE 13 WESTERN EUROPE PERICARDITIS MARKET SHARE BY COUNTRY, 2020 (%) 75
FIGURE 14 ASIA-PACIFIC PERICARDITIS MARKET SHARE BY REGION, 2020 (%) 97
FIGURE 15 MIDDLE EAST & AFRICA PERICARDITIS MARKET SHARE BY REGION, 2020 (%) 117
This table of content is tentative and subject to change as the research progresses.
Please Note: Financial details of company cannot be provided if the information of the company is not available in public domain and or reliable source.
Global Pericarditis Market: Company Landscape
The global pericarditis market is characterized by the presence of many global, regional, and local vendors. The market is highly competitive with all the players competing to gain the market share. Intense competition, rapid advances in technology, frequent changes in government policies, and environmental regulations are key factors that confront market growth. The vendors compete based on cost, quality, and reliability. It is decisive for vendors to provide cost-efficient and high-quality products, to survive and succeed in an intensely competitive and growing market environment.
The growth of market vendors is dependent on market conditions, government support, and industry development. Thus, vendors should focus on expanding geographically and improving their products. They primarily focus on the development of novel products. Although international players are dominating the market, regional and foreign players with small market shares also have a presence. The international players are likely to strengthen their presence worldwide through acquisitions during the forecast period. It has also been forecast that improvement of the global economic scenario combined with efforts to enhance infrastructure in emerging nations, is fueling the market growth, thereby making it an ideal time for new products and to increase the global market share.
Many leading players are concentrated in the Americas owing to the strengthening healthcare system, well-established market, high healthcare expenditures, and numerous opportunities for growth. These players have expanded their market in other regions as well. Furthermore, companies such as Pfizer Inc., AstraZeneca Plc, Novartis International AG, Allergan plc., and Merck & Co., Inc. are top five market players in this market. Apart from this, Bayer AG, Reckitt Benckiser Group Plc., PerkinElmer, Inc., FUJIFILM Holdings Corporation, Sanofi, and Johnson & Johnson Services, Inc. are some of the well-established players in the global pericarditis market.
Pfizer Inc. (Pfizer) is a leading research-based biopharmaceutical company that develops medicines and vaccines for a wide range of medical disciplines including cardiology, immunology, oncology, diabetology/endocrinology, and neurology. Pfizer additionally teams up with healthcare providers, governments, and local communities to support and expand access to reliable and affordable healthcare around the world. The company operates worldwide in the Americas, Europe, Asia-Pacific, and the Middle East and Africa. In July 2017 Pfizer Inc. extended the collaboration with Catalent, Inc, a global provider of advanced delivery technologies and development solutions for drugs, biologics, and consumer health products for the development and manufacture of Advil Liqui-Gels.
Novartis International AG (Novartis) is a Swiss multinational pharmaceutical company that researches, develops, manufactures, and distributes a wide range of healthcare products globally. The company operates through three segments, namely, innovative medicines, Sandoz, and Alcon. The company provides products that find applications in cancer, cardio-metabolic, immunology and dermatology, ophthalmology, neuroscience, and respiratory diseases.
Allergan plc. (Allergan) is a pharmaceutical company with a motive of manufacturing, developing, and commercializing pharmaceutical products, biological products, and devices for patients worldwide. The company has a wide range of products which provide effective treatments for the central nervous system, eye care, medical aesthetics and dermatology, gastroenterology, women's health, urology, and anti-infective therapeutic categories. The company has operations across the globe in regions such as Europe, Africa, Americas, and Asia-Pacific.
Merck & Co., Inc. (Merck) is also known as MSD outside the US and Canada. The company operates through its four segments, namely, pharmaceutical, animal health, healthcare services, and alliances. The company offers therapeutic and preventive agents to treat arthritis and pain, cardiovascular diseases, type 2 diabetes, asthma, nasal allergy symptoms, allergic rhinitis, and other diseases. Merck works with clients and works in more than 140 countries to provide inventive healthcare products.